Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Depreciation & Amortization (CF): 2021-2025

Historic Depreciation & Amortization (CF) for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to $53,202.

  • InMed Pharmaceuticals' Depreciation & Amortization (CF) fell 2.52% to $53,202 in Q3 2025 from the same period last year, while for Sep 2025 it was $211,462, marking a year-over-year decrease of 3.59%. This contributed to the annual value of $212,839 for FY2025, which is 3.08% down from last year.
  • As of Q3 2025, InMed Pharmaceuticals' Depreciation & Amortization (CF) stood at $53,202, which was up 0.85% from $52,752 recorded in Q2 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Depreciation & Amortization (CF) peaked at $55,231 during Q4 2023, and registered a low of $28,532 during Q3 2021.
  • Over the past 3 years, InMed Pharmaceuticals' median Depreciation & Amortization (CF) value was $53,463 (recorded in 2023), while the average stood at $53,618.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first soared by 71.91% in 2022, then dropped by 4.97% in 2023.
  • InMed Pharmaceuticals' Depreciation & Amortization (CF) (Quarterly) stood at $49,797 in 2021, then decreased by 1.50% to $49,049 in 2022, then rose by 12.60% to $55,231 in 2023, then dropped by 3.67% to $53,203 in 2024, then dropped by 2.52% to $53,202 in 2025.
  • Its last three reported values are $53,202 in Q3 2025, $52,752 for Q2 2025, and $52,305 during Q1 2025.